Targeting Siah2 as Novel Therapy for Metastatic Prostate Cancer
Technical Report,30 Sep 2014,29 Sep 2017
Cedars-Sinai Medical Center Los Angeles United States
Pagination or Media Count:
The goal of this project was to develop a novel means to inhibit prostate cancer development and progression. The development of Siah12 inhibitors to the ubiquitin ligase Siah12 was advanced by the ability to develop aSiah12 inhibitory peptide that effectively inhibits Siah12 activity, which was found to effectively attenuate the growth of prostate cancer tumors in vivo when transplanted subcutaneously or orthotopically into the prostate site. The assessment of the Siah12 inhibitory reagents was performed in vitro, in cultures and in genetic models of mouse as in human PDX tumors in our lab as by the Partnering PIs, Drs. Martin Gleave and Neil Bhowmick at the two respective sites. Most of my labs attention was given to the development and assessment of small molecule inhibitors to Siah2 as a mean to complement the work performed with the inhibitory peptide. The goal has been to secure the first-in-class inhibitor of the ubiquitin ligase that can be used in vivo for the inhibition of prostate cancer.
- Medicine and Medical Research